萬隆控股集團(00030.HK):與雲南白藥訂立諒解備忘錄 雙方共設工業大麻合營公司
格隆匯4月26日丨萬隆控股集團(00030.HK)宣佈,於2021年4月23日,公司與關連人士雲南白藥(000538.SZ)訂立不具法律約束力的諒解備忘錄,以成立一家將從事工業大麻相關產業鏈及供應鏈相關業務的合營公司。合營公司將以在雲南省成立有限責任公司的形式成立。雲南白藥及公司將分別持有合營公司不多於49%及不少於51%股權。成立合營公司後,合營公司的財務業績將會與集團財務報表綜合入賬。
公司董事認為,利用雲南白藥所擁有的現有基礎設施,包括大麻種植場和大麻種植及萃取設備,對集團有利。董事認為,訂立諒解備忘錄符合公司及其股東的整體利益,因為諒解備忘錄項下擬進行的交易(倘落實進行)將能讓集團加快進軍大麻種植業務、加強其研發策略以及鞏固其作為中國生產大麻的先導廠商之一的市場地位,從而為集團的現有產品組合添加新產品及為集團創造新的發展機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.